Nonexposed Variant of Bisphosphonate-associated Osteonecrosis of the Jaw: A Case Series

被引:167
|
作者
Fedele, Stefano [1 ]
Porter, Stephen R.
D'Aiuto, Francesco
Aljohani, Suad
Vescovi, Paolo [2 ]
Manfredi, Maddalena [2 ]
Arduino, Paolo G. [3 ]
Broccoletti, Roberto [3 ]
Musciotto, Anna [4 ]
Di Fede, Olga [4 ]
Lazarovici, Tony S. [5 ]
Campisi, Giuseppina [4 ]
Yarom, Naom [5 ,6 ]
机构
[1] UCL, Eastman Dent Inst, Oral Med Unit, Div Maxillofacial Diagnost Med & Surg Sci, London WC1X 8LD, England
[2] Univ Parma, Unit Oral Med Pathol Laser Assisted Surgery Parma, I-43100 Parma, Italy
[3] Univ Turin, Lingotto Dent Inst, Oral Med Sect, Dept Biomed Sci & Human Oncol, Turin, Italy
[4] Univ Palermo, Dept Stomatol Sci, Oral Med Sect, Palermo, Italy
[5] Chaim Sheba Med Ctr, Dept Oral & Maxillofacial Surg, IL-52621 Tel Hashomer, Israel
[6] Tel Aviv Univ, Sch Dent Med, Dept Oral Pathol & Oral Med, IL-69978 Tel Aviv, Israel
来源
AMERICAN JOURNAL OF MEDICINE | 2010年 / 123卷 / 11期
关键词
Avascular necrosis; Bisphosphonates; Jawbones; Jaws; Mandible; Maxilla; Osteochemonecrosis; Osteonecrosis; RISK-FACTORS; ORAL BISPHOSPHONATES; MULTIPLE-MYELOMA; BEAGLE DOGS; CANCER; HEAD;
D O I
10.1016/j.amjmed.2010.04.033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: To report a case series of patients with the nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw-a form of jaw osteonecrosis that does not manifest with necrotic bone exposure/mucosal fenestration. METHODS: Among 332 individuals referred to 5 clinical centers in Europe because of development of jawbone abnormalities after or during exposure to bisphosphonates, we identified a total of 96 patients who presented with the nonexposed variant of osteonecrosis. Relevant data were obtained via clinical notes; radiological investigations; patients' history, and referral letters. RESULTS: The most common clinical feature of nonexposed osteonecrosis was jaw bone pain (88/96; 91.6%); followed by sinus tract (51%), bone enlargement (36.4%); and gingival swelling (17.7%). No radiological abnormalities were identified in 29.1% (28/96) of patients. In 53.1% (51/96) of the patients; nonexposed osteonecrosis subsequently evolved into frank bone exposure within 4.6 months (mean; 95% confidence interval; 3.6-5.6). CONCLUSIONS: Clinicians should be highly vigilant to identify individuals with nonexposed osteonecrosis, as the impact on epidemiological data and clinical trial design could be potentially significant. Although the present case series represents approximately 30% of all patients with bisphosphonates-associated osteonecrosis observed at the study centers, further population-based prospective studies are needed to obtain robust epidemiological figures. (C) 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine (2010) 123, 1060-1064
引用
收藏
页码:1060 / 1064
页数:5
相关论文
共 50 条
  • [31] Bisphosphonate-associated Osteonecrosis of Jaw Reoccurrence after Methotrexate Therapy: A Case Report
    Alsalleeh, Fand
    Keippel, Jeffery
    Adams, Lyde
    Bavitz, Bruce
    JOURNAL OF ENDODONTICS, 2014, 40 (09) : 1505 - 1507
  • [32] Bisphosphonate-associated osteonecrosis of the jaw [Bisphosphonatassoziierte Osteonekrose des Kiefers]
    Abu-Id M.H.
    Açil Y.
    Gottschalk J.
    Kreusch T.
    Mund-, Kiefer- und Gesichtschirurgie, 2006, 10 (2): : 73 - 81
  • [33] Bisphosphonate-associated Osteonecrosis of the Jaw cases in South Korea.
    Chung, Y.
    Kwon, Y.
    Lee, J.
    Kim, D.
    Lee, S.
    Lee, B.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S210 - S210
  • [34] Bisphosphonate-associated osteonecrosis of the jaw. A proposal for conservative treatment
    Bocanegra Perez, Sacramento
    Vicente Barrero, Mario
    Sosa Hernandez, Manuel
    Knezevic, Milan
    Castellano Navarro, Jose Maria
    Rodriguez Millares, Jose
    MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, 2008, 13 (12): : E770 - E773
  • [35] Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw
    Narvaez, J.
    Narvaez, J. A.
    Gomez-Vaquero, C.
    Nolla, J. M.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (02) : 731 - 733
  • [36] Teriparatide’s role in the management of bisphosphonate-associated osteonecrosis of the jaw
    G. Subramanian
    S. Y. P. Quek
    Osteoporosis International, 2012, 23 : 2727 - 2728
  • [37] Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?
    Reid, Ian R.
    Bolland, Mark J.
    Grey, Andrew B.
    BONE, 2007, 41 (03) : 318 - 320
  • [38] Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw
    J. Narváez
    J. A. Narváez
    C. Gómez-Vaquero
    J. M. Nolla
    Osteoporosis International, 2013, 24 : 731 - 733
  • [39] Tetraparesis after surgical treatment of bisphosphonate-associated osteonecrosis of the jaw
    Zaami, Simona
    Busardo, Francesco P.
    Amatruda, Alfonso
    Ricci, Giovanna
    Esposito, Vincenzo
    JOURNAL OF NEUROSURGICAL SCIENCES, 2018, 62 (01) : 97 - 99
  • [40] Oral Health Risk Factors for Bisphosphonate-Associated Jaw Osteonecrosis
    Tsao, Claudine
    Darby, Ivan
    Ebeling, Peter R.
    Walsh, Katrina
    O'Brien-Simpson, Neil
    Reynolds, Eric
    Borromeo, Gelsomina
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2013, 71 (08) : 1360 - 1366